Keywords: |
immunohistochemistry; signal transduction; mitogen activated protein kinase; protein kinase b; cancer survival; protein phosphorylation; treatment outcome; oncoprotein; gene mutation; proto-oncogene proteins; clinical trial; cigarette smoking; raf protein; antineoplastic agents; drug approval; note; drug targeting; antineoplastic agent; protein function; cell proliferation; metabolism; cell survival; gene targeting; enzyme inhibition; lung non small cell cancer; carcinoma, non-small-cell lung; lung neoplasms; epidermal growth factor receptor; editorial; receptor, epidermal growth factor; in vitro study; drug effect; enzyme inhibitor; protein serine threonine kinase; protein tyrosine kinase; drug selectivity; phosphatidylinositol 3 kinase; prediction; drug receptor binding; lung tumor; gene expression regulation; gene activation; gene expression regulation, neoplastic; drug antagonism; drug mechanism; enzyme inhibitors; protein-serine-threonine kinases; drug response; proto-oncogene proteins c-akt; gefitinib; tyrosine kinase receptor; prediction and forecasting; predictive value of tests; binding site; lung alveolus cell carcinoma; ras protein; thorax radiography; sex difference; protein-tyrosine kinases; adenosine triphosphate; quinazolines; drug sensitivity; mitogen activated protein kinase kinase; mitogen-activated protein kinase kinases; quinazoline derivative; downstream processing; akt1 protein, human; humans; prognosis; human; priority journal
|